Our newsroom provides you with the latest information about the German Breast Group. This section of the website also includes photographic material and information about our events. In addition, our Annual Scientific Reports, which provide an overview of our research activities, can be downloaded here.
We are happy to present our work at the San Antonio Breast Cancer Symposium , December 7-10
We are happy to present our work at ESMO 2021, September 16-21th
We are delighted to inform you that our analysis on the utility of the CPS + EG score in triple-negative breast cancer patients has been published in European Journal of Cancer
We are pleased to inform you that a pooled analysis of patients with HER2-low-positive breast cancer has been published in The Lancet Oncology
A prospective analysis on chemotherapy-induced ovarian failure in young women with early breast cancer has been published in European Journal of Cancer
A pooled analysis on therapy response and prognosis of patients with low HR-positive, HER2-negative early breast cancer has been published in European Journal of Cancer
We are happy to inform you that results of several research projects from GBG and collaborative groups will be presented at the upcoming ASCO Annual Meeting 2021, which will take place from 4 to 8 June.
We are delighted to inform you that the first results of the randomized phase III PenelopeB trial have been published in Journal of Clinical Oncology.
An analysis including breast cancer patients with brain metastases from the BMBC registry has been published in Cancers
Registration for the ESMO Breast Cancer Virtual Meeting, taking place 5-8 May 2021 is now open.
A translational research project investigating genomic patterns of mutational signatures in breast cancer patients from GeparSepto trial has been published in Annals of Oncology.
We are delighted to inform you that final results of the first randomized phase II MALE trial have been published in JAMA Oncology.
IDMC has concluded that OlympiA trial crossed superiority boundary for invasive disease-free survival vs. placebo at planned interim analysis. OlympiA Phase III trial of Lynparza in the adjuvant treatment of BRCA-mutated HER2-negative high-risk early breast cancer will be analysed and reported early.
The GBG Annual Meeting will be held february 24th to 26th 2021 as a virtual conference.
A retrospective analysis investigating the effect of germline BRCA1/2 mutations on severe haematological toxicities in TNBC patients treated with chemotherapy has been published in European Journal of Cancer.
A new consortium of the EU Innovative Medicines Initiative (IMI) will establish the biggest database of pathology images to accelerate the development of artificial intelligence in medicine.
The 17th St.Gallen International Breast Cancer Conference is going fully virtual!
Data on GBG study PenelopeB and several collaborative projects will be presented at the SABCS Virtual Meeting 2020.
We are delighted to inform you that results from GeparOLA trial have been published in Annals of Oncology.
First patient included.